Dr Sue-Ann Ng, Associate Consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, speaks to Roshini Claire Anthony on the multisystemic autoimmune disease that is systemic sclerosis (SSc) and the importance of early identification of the condition.
Roshini Claire Anthony speaks with Dr Annie Law, a consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, on how primary care physicians can help in the management of systemic lupus erythematosus (SLE).
A 36-year-old banker with good past health presented to our rheumatology clinic with a 6-month history of bilateral wrist pain. He initially sought medical attention in the private sector for a 2-month history of bilateral symmetrical wrist pain and swelling.
Dr. Priscilla Wong, Dr. Lydia Tam, Prof. LS Tam, 20171110000000
This case report highlights that psoriatic arthritis is a heterogenous disease affecting multiple disease domains, and effective treatment requires thorough assessment of each of these different domains.
Spinal fractures are often the result of underlying osteoporosis. Radha Chitale spoke with Dr. Hee Hwan Tak, medical director and senior consultant at the Pinnacle Spine & Scoliosis Centre at Mount Elizabeth Medical Centre, about managing osteoporotic spinal fractures in primary care.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Rheumatology digital copy today!
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.